ABEONA THERAPEUTICS INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
ABEONA THERAPEUTICS INC. (ABEO) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 7.81 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-06-30 was 8.20M shares, a 0.42% increase year-over-year.
- ABEONA THERAPEUTICS INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-06-30 was 8.17M shares.
- ABEONA THERAPEUTICS INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2025 was 7.81M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 7.81M shares 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | 8.05M shares 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | 8.20M shares 10-Q · filed 2026-08-13 | 8.20M shares 10-Q · filed 2026-08-13 | |||
| 2024-06-30 | 8.17M shares 10-Q · filed 2025-08-14 | 8.17B shares 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |